Reviva's Brilaroxazine Phase III Data Show Strong Efficacy and Safety, NDA Filing Planned by 2028
核心洞察
Reviva Pharmaceuticals reported that brilaroxazine demonstrated robust and sustained efficacy with a superior safety profile in phase III trials in schizophrenia (搜索).
The phase III data showed low relapse and discontinuation rates, according to the company's presentation at the Lytham Partners Fall 2026 Investor Conference.
Reviva plans a new proprietary formulation and extended patent life, with an NDA filing targeted for late 2028 and a Nasdaq up-listing anticipated in 2027.
Reviva Pharmaceuticals Holdings (搜索) reported that brilaroxazine showed robust and sustained efficacy along with a superior safety profile in phase III trials in schizophrenia (搜索). The company said the trials were marked by low relapse and discontinuation rates.
Development plans include a new proprietary formulation of brilaroxazine and extended patent life. Reviva is targeting an NDA filing for brilaroxazine by late 2028, with a Nasdaq up-listing anticipated in 2027.
The details were presented in the company's audio transcript for the Lytham Partners Fall 2026 Investor Conference, dated September 29, 2026.